{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cytochrome+P450+%28CYP%29+Cocktail", "query": { "intervention": "Cytochrome P450 (CYP) Cocktail" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 18, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cytochrome+P450+%28CYP%29+Cocktail&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-27T16:40:04.893Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05657613", "title": "Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug Interactions" ], "interventions": [ { "name": "CYP450 Cocktail and Transporter Substrates with Pacritinib", "type": "DRUG" }, { "name": "Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib", "type": "DRUG" }, { "name": "Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CTI BioPharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "18 Years to 55 Years · Male only" }, "enrollment_count": 60, "start_date": "2023-01-03", "completion_date": "2023-06-08", "has_results": false, "last_update_posted_date": "2024-10-17", "last_synced_at": "2026-09-27T16:40:04.893Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05657613" }, { "nct_id": "NCT03718884", "title": "A Study of Mirikizumab in Participants With Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "Drug Cocktail", "type": "DRUG" }, { "name": "Mirikizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2018-10-23", "completion_date": "2019-10-28", "has_results": true, "last_update_posted_date": "2024-01-29", "last_synced_at": "2026-09-27T16:40:04.893Z", "location_count": 3, "location_summary": "Anaheim, California • DeLand, Florida • High Point, North Carolina", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "High Point", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03718884" }, { "nct_id": "NCT03358706", "title": "A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Crohn Disease", "Ulcerative Colitis" ], "interventions": [ { "name": "Ustekinumab IV Infusion", "type": "DRUG" }, { "name": "Ustekinumab SC Injection", "type": "DRUG" }, { "name": "Midazolam 2 mg", "type": "DRUG" }, { "name": "Warfarin 10 mg", "type": "DRUG" }, { "name": "Vitamin K 10 mg", "type": "DRUG" }, { "name": "Omeprazole 20 mg", "type": "DRUG" }, { "name": "Dextromethorphan 30 mg", "type": "DRUG" }, { "name": "Caffeine 100 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 28, "start_date": "2018-02-02", "completion_date": "2021-11-22", "has_results": false, "last_update_posted_date": "2025-08-21", "last_synced_at": "2026-09-27T16:40:04.893Z", "location_count": 3, "location_summary": "Cypress, California • Miami Springs, Florida • Durham, North Carolina", "locations": [ { "city": "Cypress", "state": "California" }, { "city": "Miami Springs", "state": "Florida" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03358706" }, { "nct_id": "NCT06693960", "title": "Evaluating the Pharmacokinetics of Oregano and Potential Oregano-drug Interactions Using a Drug Cocktail Approach", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Interaction" ], "interventions": [ { "name": "Oregano", "type": "DIETARY_SUPPLEMENT" }, { "name": "Drug cocktail", "type": "DRUG" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG" ], "sponsor": "Washington State University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 16, "start_date": "2024-09-26", "completion_date": "2027-01-31", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-09-27T16:40:04.893Z", "location_count": 1, "location_summary": "Spokane, Washington", "locations": [ { "city": "Spokane", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06693960" }, { "nct_id": "NCT03333824", "title": "Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumours" ], "interventions": [ { "name": "CYP1A2 (caffeine)", "type": "DRUG" }, { "name": "CYP2C19 (omeprazole)", "type": "DRUG" }, { "name": "CYP3A (midazolam)", "type": "DRUG" }, { "name": "Kytril (granisetron)", "type": "DRUG" }, { "name": "Wee-1 kinase inhibitor AZD1775", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 33, "start_date": "2017-12-01", "completion_date": "2019-01-22", "has_results": false, "last_update_posted_date": "2019-03-25", "last_synced_at": "2026-09-27T16:40:04.893Z", "location_count": 7, "location_summary": "Bingham Farms, Michigan • Detroit, Michigan • Lebanon, New Hampshire + 4 more", "locations": [ { "city": "Bingham Farms", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT03333824" }, { "nct_id": "NCT01473888", "title": "A Study To Evaluate The Effect of T89(Dantonic®)On P450 Enzymes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Stable Angina" ], "interventions": [ { "name": "T89(Dantonic)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tasly Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 24, "start_date": "2011-01", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2012-11-08", "last_synced_at": "2026-09-27T16:40:04.893Z", "location_count": 1, "location_summary": "Tacoma, Washington", "locations": [ { "city": "Tacoma", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01473888" }, { "nct_id": "NCT02688088", "title": "A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasm Metastasis" ], "interventions": [ { "name": "Drug Cocktail", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2016-03-08", "completion_date": "2021-01-06", "has_results": true, "last_update_posted_date": "2022-10-18", "last_synced_at": "2026-09-27T16:40:04.893Z", "location_count": 5, "location_summary": "Denver, Colorado • Indianapolis, Indiana • Fairway, Kansas + 2 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Fairway", "state": "Kansas" }, { "city": "Dallas", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02688088" }, { "nct_id": "NCT03792841", "title": "Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer", "Prostate Cancer" ], "interventions": [ { "name": "acapatamab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Cytochrome P450 (CYP) Cocktail", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 212, "start_date": "2019-02-05", "completion_date": "2023-06-29", "has_results": false, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-09-27T16:40:04.893Z", "location_count": 13, "location_summary": "Campbell, California • Duarte, California • Long Beach, California + 9 more", "locations": [ { "city": "Campbell", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03792841" }, { "nct_id": "NCT05891119", "title": "Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Caffeine", "type": "DIETARY_SUPPLEMENT" }, { "name": "Metoprolol", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" }, { "name": "Vitamin K", "type": "DIETARY_SUPPLEMENT" }, { "name": "Omeprazole", "type": "DRUG" }, { "name": "Rocatinlimab", "type": "DRUG" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 21, "start_date": "2023-06-03", "completion_date": "2025-02-12", "has_results": false, "last_update_posted_date": "2025-12-23", "last_synced_at": "2026-09-27T16:40:04.893Z", "location_count": 7, "location_summary": "North Hollywood, California • DeLand, Florida • Hialeah, Florida + 4 more", "locations": [ { "city": "North Hollywood", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Dilworth", "state": "Minnesota" }, { "city": "Camp Hill", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05891119" }, { "nct_id": "NCT02397382", "title": "Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "Guselkumab", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" }, { "name": "Omeprazole", "type": "DRUG" }, { "name": "Dextromethorphan", "type": "DRUG" }, { "name": "Caffeine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 16, "start_date": "2015-06-18", "completion_date": "2016-08-31", "has_results": false, "last_update_posted_date": "2017-09-20", "last_synced_at": "2026-09-27T16:40:04.893Z", "location_count": 8, "location_summary": "Anniston, Alabama • North Hollywood, California • Orlando, Florida + 5 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "North Hollywood", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "High Point", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02397382" } ] }